封面
市場調查報告書
商品編碼
2136467

2016-2026年婦科領域的合作與授權協議

Gynecology Collaboration and Licensing Deals 2016-2026

出版日期: | 出版商: Current Partnering | 英文 100+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

讓我們透過 155 個案例研究,利用有關合作和許可協議的信息,來了解婦科領域合作的趨勢。

《2016-2026 年婦科合作與許可協議》提供了有關婦科領域資產、技術和開發計劃的 155 項合作協議的全面資訊。

我們在婦科領域的合作涵蓋了女性健康這一專業且不斷發展的領域,包括廣泛的治療適應症、技術和發展策略。

本報告將這些趨勢匯總到一個資源中,使用戶能夠了解哪些公司正在合作,哪些婦科機會正在吸引關注,交易結構是什麼,披露了哪些財務條款,以及交易如何根據治療適應症、技術和開發階段而有所不同。

這份報告不只是簡單地列出了交易清單;它結合了全面的市場交易分析和財務基準、主要交易商的信息、詳細的交易記錄以及公開的合約文件。

本報告為婦科和女性健康領域的企業發展、許可、交易來源和評估、公司策略、研發策略、競爭情報分析以及參與合作的法律團隊提供可操作的資訊和基準資源。

了解婦科領域合作的趨勢。

本報告分析了2016年至2026年婦科領域的交易狀況,內容包括:

  • 婦科領域合作的年度趨勢
  • 按交易類型分類的交易趨勢
  • 產業部門
  • 合作關係發展階段
  • 技術類型
  • 適應症
  • 婦科領域最活躍的交易商
  • 根據已揭露的交易金額,主要交易金額
  • 婦科領域合作活動的趨勢
  • 這使用戶能夠確定他們的活動集中在哪些方面,並了解哪些公司、技術、開發階段和治療領域正在吸引合作興趣。
  • 婦科領域交易財務資訊的基準分析
  • 財務條款可能因資產、開發階段、技術、授予的權利以及交易的整體結構而有很大差異。

本報告對已揭露的財務狀況進行了詳細分析,包括以下項目:

  • 交易總額
  • 預付款
  • 里程碑付款
  • 版稅率
  • 透過分析這些基準背後的具體交易,用戶可以深入了解所揭露的經濟狀況的背景。
  • 這為內部基準測試、機會評估、交易準備和談判提供了一個現實的基準。
  • 財務基準只有在結合類似交易的結構和情況進行解讀時才最有用,而不僅僅是作為平均值。本報告提供了建立這種背景所需的基礎交易資訊。
  • 確定婦科領域的關鍵交易撮合者和潛在的未來夥伴。
  • 本報告列出了在婦科領域合作活動最活躍的公司,並提供交易歷史記錄,以便用戶可以調查這些公司過去的活動。

這有助於用戶識別以下內容:

  • 積極尋求婦科和女性健康領域商機的公司。
  • 潛在的許可和聯合開發合作夥伴
  • 我們曾多次與相關機構就相關適應症合作
  • 積極參與相關開發階段的公司
  • 對特定技術或方法表現出興趣的交易商
  • 競爭對手正在推廣相關的外部創新策略
  • 對於在婦科領域尋求資產和技術合作夥伴的公司而言,過去的交易歷史可以提供寶貴的見解,了解哪些組織對類似的機會表現出了興趣。
  • 比較不同治療適應症和治療目標的合作活動。
  • 婦科領域涵蓋多種治療機會,每種機會都有不同的臨床、競爭和商業性趨勢。
  • 本報告基於治療領域和治療標靶分析合作關係,使用戶能夠識別與特定項目和策略關注事項最相關的交易,而不是僅依賴廣泛的市場層級基準。
  • 透過結合基於技術和發展階段的分析,用戶可以發現更多有意義的類似交易和潛在的未來合作夥伴關係。
  • 了解婦科領域合約的結構
  • 本報告涵蓋合作研究、授權、開發、調查和其他合作交易。

根據交易詳情和資訊披露,用戶可以調查以下方面:

  • 授予和保留的權利
  • 研發職責
  • 授權權
  • 獨家版權
  • 區域權利
  • 智慧財產
  • 發展和監管義務
  • 負責生產和供應
  • 商業化權利
  • 金錢補償
  • 里程碑和版稅
  • 管治
  • 合約期限和終止條款
  • 這些例子對於考慮婦科領域合作的合適框架將很有幫助。
  • 從實際合約文件中學習
  • 本報告提供部分婦科相關交易的原始合約文件(如有)。

這些合約提供的資訊遠比簡單的標題公告所能展現的要詳細得多,使用戶能夠了解公司如何記錄諸如以下事項:

  • 權利範圍
  • 發展義務
  • 智慧財產
  • 獨家版權
  • 財務狀況
  • 里程碑達成條件
  • 特許權使用費規定
  • 商業化權利
  • 合約終止及其他談判事項
  • 對於準備和談判婦科領域合作研究或授權協議的團隊來說,取得實際的合約條款可以提供關於類似交易實際結構方式的寶貴見解。
  • 綜合婦科交易目錄
  • 本報告包含婦科領域 155 項合作與授權協議的綜合目錄,為識別相關的領先交易提供專門資源。

在以下條件下可以查看交易記錄:

  • 公司
  • 技術類型
  • 治療適應症或標靶
  • 合約揭露狀態
  • 每筆交易都與其底層交易記錄相關聯,從而可以存取詳細的交易資訊和相關的合約文件(如有)。
  • 誰該使用這份報告?
  • 業務拓展與授權團隊
  • 識別婦科領域類似的交易、有前景的合作夥伴以及相關的交易結構。
  • 研究與評估團隊
  • 我們將根據相關適應症、技術和發展階段,確定哪些公司正在積極探索女性健康領域的商機。
  • 尋求合作夥伴的生技公司
  • 找出對類似婦科相關資產或技術表現出明顯興趣的組織。
  • 企業策略與研發策略團隊
  • 我們將了解競爭對手和潛在合作夥伴如何透過外部創新在女性健康領域建立其產品組合。
  • 競爭情報與市場情報團隊
  • 按公司、適應症、目標、開發階段和技術追蹤合作趨勢,以了解不斷變化的策略重點。
  • 法律及交易團隊
  • 我們將仔細審查公開的合約和以往的合約結構,以幫助您準備和談判交易。
  • 我們將把整個市場與婦科相關的資訊轉化為公司專屬的洞察。
  • 符合資格的客戶將收到 Current Partnering 的報告,以及為高階主管量身訂製的合作關係簡報。
  • 本簡報將說明婦科領域交易的基本原理,並將其應用於您自己的資產、技術、適應症、目標受眾或合作目標。
  • 如有需要,我們可以提供相關的類似交易、潛在的未來合作關係、競爭對手的活動、發展階段分析、交易結構、財務基準、忠誠度分析、合約見解以及其他專門為您情況選擇的資訊。
  • 請索取樣本或聯絡 Current Partnering 討論報告內容以及我們是否可以為貴公司提供客製化分析。

目錄

執行摘要

第1章:引言

第2章:婦科領域交易趨勢

  • 迄今為止婦科領域合作的趨勢
  • 按交易類型分類的婦科領域合作關係
  • 婦科領域合作的產業特定趨勢
  • 婦科領域不同發展階段的合作
  • 按技術類型分類的婦科領域合作
  • 基於治療指徵的婦科領域合作

第3章 婦科領域合夥企業的財務條件

  • 婦科領域合作關係的揭露財務條款
  • 婦科領域的合作關係總數
  • 婦科領域合作的預付款
  • 婦科領域合作的里程碑付款
  • 婦科領域的專利使用費率

第4章:婦科領域的主要交易與交易商

  • 在婦科領域合作最活躍的公司
  • 婦科領域最活躍的交易商名單
  • 婦科主要領域的交易額:按金額

第5章:婦科領域合約文件目錄

  • 婦科領域合作項目,且有相關合約文件可供查閱。

第6章:基於治療標靶的婦科領域交易

  • 基於婦科治療目標的交易
  • 交易目錄
  • 交易目錄 - 婦科領域的交易記錄,依公司名稱(A-Z)排序
  • 交易目錄 - 按技術類型分類的婦科領域交易
  • 交易類型的定義
  • 關於生物製藥研究
  • Current Partnering
  • Current Agreements
  • 理想合作夥伴近期報告標題
簡介目錄
Product Code: CP2211

Understand the gynecology partnering landscape using intelligence from 155 real-world collaboration and licensing deals.

Gynecology Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 155 partnering deals involving gynecology assets, technologies and development programs.

Gynecology partnering spans a specialist and evolving area of women's health, encompassing a range of therapeutic indications, technologies and development strategies.

The report brings this activity together in one resource, enabling users to understand who is partnering, which gynecology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in gynecology and women's health partnering.

Understand the gynecology partnering landscape

The report analyzes gynecology dealmaking from 2016 to 2026, including:

  • Trends in gynecology partnering by year
  • Deal activity by deal type
  • Industry sector
  • Stage of development at the time of partnering
  • Technology type
  • Therapeutic indication
  • Most active gynecology dealmakers
  • Leading deals by disclosed value
  • How gynecology partnering activity is evolving
  • This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
  • Benchmark gynecology deal financials
  • Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

  • Headline deal values
  • Upfront payments
  • Milestone payments
  • Royalty rates
  • Users can investigate the individual transactions behind these benchmarks to understand the context surrounding the disclosed economics.
  • This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
  • Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
  • Identify leading gynecology dealmakers and prospective partners
  • The report identifies the most active companies in gynecology partnering and provides transaction histories that enable users to investigate their previous activity.

This can help users identify:

  • Companies actively seeking gynecology and women's health opportunities
  • Prospective licensing and collaboration partners
  • Organizations repeatedly partnering in relevant indications
  • Companies active at relevant stages of development
  • Dealmakers demonstrating interest in particular technologies or approaches
  • Competitors pursuing related external innovation strategies
  • For companies seeking to partner a gynecology asset or technology, previous deal activity can provide useful evidence of which organizations have demonstrated an appetite for comparable opportunities.
  • Compare partnering activity across therapeutic indications and targets
  • Gynecology encompasses a range of distinct therapeutic opportunities with differing clinical, competitive and commercial dynamics.
  • The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad market-level benchmarks and identify transactions most relevant to a particular program or strategic interest.
  • Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
  • Understand how gynecology agreements are structured
  • The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

  • Rights granted and retained
  • Research and development responsibilities
  • Licensing rights
  • Exclusivity
  • Geographic rights
  • Intellectual property
  • Development and regulatory obligations
  • Manufacturing and supply responsibilities
  • Commercialization rights
  • Financial consideration
  • Milestones and royalties
  • Governance
  • Term and termination provisions
  • These real-world examples provide useful reference points when considering the appropriate structure for a gynecology partnership.
  • Learn from real-world contract documents
  • Where publicly available, the report provides access to underlying contract documents for selected gynecology transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

  • Scope of rights
  • Development obligations
  • Intellectual property
  • Exclusivity
  • Financial terms
  • Milestone triggers
  • Royalty provisions
  • Commercialization rights
  • Termination and other negotiated provisions
  • For teams preparing or negotiating a gynecology collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
  • Comprehensive gynecology deal directory
  • The report includes a comprehensive directory of 155 gynecology collaboration and licensing deals, providing a focused resource for identifying relevant precedent transactions.

Deals can be reviewed by:

  • Company
  • Technology type
  • Therapeutic indication or target
  • Contract availability
  • Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
  • Who should use this report?
  • Business Development and Licensing teams
  • Identify comparable gynecology transactions, prospective partners and relevant deal structures.
  • Search and Evaluation teams
  • Understand which companies are actively seeking women's health opportunities across relevant indications, technologies and development stages.
  • Biotechnology Companies Seeking Partners
  • Identify organizations with demonstrated interest in comparable gynecology assets and technologies.
  • Corporate and R&D Strategy teams
  • Understand how competitors and prospective partners are building women's health portfolios through external innovation.
  • Competitive and Market Intelligence teams
  • Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
  • Legal and Transaction teams
  • Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
  • Turn market-wide gynecology intelligence into company-specific insight
  • For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
  • The briefing applies the underlying gynecology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
  • Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
  • Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gynecology dealmaking

  • 2.1. Introduction
  • 2.2. Gynecology partnering over the years
  • 2.3. Gynecology partnering by deal type
  • 2.4. Gynecology partnering by industry sector
  • 2.5. Gynecology partnering by stage of development
  • 2.6. Gynecology partnering by technology type
  • 2.7. Gynecology partnering by therapeutic indication

Chapter 3 - Financial deal terms for gynecology partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for gynecology partnering
  • 3.3. Gynecology partnering headline values
  • 3.4. Gynecology deal upfront payments
  • 3.5. Gynecology deal milestone payments
  • 3.6. Gynecology royalty rates

Chapter 4 - Leading gynecology deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in gynecology partnering
  • 4.3. List of most active dealmakers in gynecology
  • 4.4. Top gynecology deals by value

Chapter 5 - Gynecology contract document directory

  • 5.1. Introduction
  • 5.2. Gynecology partnering deals where contract document available

Chapter 6 - Gynecology dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by gynecology therapeutic target
  • Deal directory
  • Deal directory - Gynecology deals by company A-Z
  • Deal directory - Gynecology deals by technology type
  • Deal type definitions
  • About Biopharma Research Ltd
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Gynecology partnering since 2016
  • Figure 2: Gynecology partnering by deal type since 2016
  • Figure 3: Gynecology partnering by industry sector since 2016
  • Figure 4: Gynecology partnering by stage of development since 2016
  • Figure 5: Gynecology partnering by technology type since 2016
  • Figure 6: Gynecology partnering by indication since 2016
  • Figure 7: Gynecology deals with a headline value
  • Figure 8: Gynecology deals with upfront payment values
  • Figure 9: Gynecology deals with milestone payment
  • Figure 10: Gynecology deals with royalty rates
  • Figure 11: Active gynecology dealmaking activity since 2016
  • Figure 12: Top gynecology deals by value since 2016